Uthever® NMN NOVEL FOOD Update Download Whitepaper

Overview

EFFEPHARM

NMN is a precursor to NAD+. NAD+ is crucial for energy production, DNA repair, and regulating various cellular processes.

Uthever® NMN, the world’s first large-scale, human clinically-proven NMN brand, has completed the EU NOVEL FOOD Public Consultation. Uthever® is pioneering the EU NOVEL FOOD application process as the first NMN brand to enter the risk assessment stage and is now pending approval. Contact us to plan ahead and get your product market-ready.

Download the whitepaper for industry insights, the latest scientific findings on NMN, and comprehensive global regulatory information.

This content is paid by Effepharm Ltd, and any views and opinions expressed do not necessarily reflect those of NutraIngredients.com

Download Now

Related Topics

IngredientsHealth

Latest Content

Related Resources

The Global Regulatory Advantage Behind UTHEVER® NMN

The Global Regulatory Advantage Behind UTHEVER® NMN

Paid for by Effepharm Ltd

White Paper

Regulatory uncertainty remains one of the biggest challenges for NMN brands. Choosing the wrong ingredient could lead to compliance risks & market restrictions.

Discover UTHEVER® NMN’s Global Regulatory Landscape

Discover UTHEVER® NMN’s Global Regulatory Landscape

Paid for by Effepharm Ltd

White Paper

NMN has long faced regulatory challenges. Today, that landscape is changing. We consistently invest in scientific research & quality development, aiming to establish UTHEVER® as the world’s most compliant NMN ingredient brand.

Supplier Info Centre

Effepharm-Ltd.jpg

For more product information visit Effepharm Ltd.